Correction to: Rimonabant reduces keratinocyte viability by induction of apoptosis and exerts topical anti-inflammatory activity in mice: Anti-inflammatory activity of rimonabant (British Journal of Pharmacology, (2011), 162, 1, (84-93), 10.1111/j.1476-5381.2010.01047.x);Rimonabant reduces keratinocyte viability by induction of apoptosis and exerts topical anti-inflammatory activity in mice

British Journal of Pharmacology

Volumn 162, Issue 1, 2011, Pages 84-93

  Malfitano, Anna Maria ^a   Sosa, Silvio ^b   Laezza, Chiara ^c   De Bortoli, Marco ^b   Tubaro, Aurelia ^b   Bifulco, Maurizio ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c Institute of Endocrinology and Experimental Oncology   (Italy)

Author keywords

apoptosis; cannabinoid receptor CB1; CB1 antagonist; cell viability; dermatitis; keratinocytes; leukocyte infiltrate; oedema

Indexed keywords

CANNABINOID 1 RECEPTOR; CROTON OIL; CYCLIN A; CYCLIN D1; CYCLIN E; CYCLINE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; RIMONABANT; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE PROGRESSION; CELL DEATH; CELL IMMORTALIZATION; CELL INFILTRATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DERMATITIS; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; EDEMA; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; LEUKOCYTE; MOUSE; NONHUMAN; OTITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 78650103672     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.14541     Document Type: Erratum

References (56)

1. Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, et al. (2007). Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 10: 870-879.
2. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th edition. Br J Pharmacol 158 (Suppl. 1), S1-S254.
3. Ahluwalia J, Urban L, Capogna M, Bevan S, Nagy I, (2000). Cannabinoid 1 receptors are expressed in nociceptive primary afferent sensory neurons. Neuroscience 100: 685-688.
4. Amaya F, Shimosato G, Kawasaki Y, Hashimoto S, Tanaka Y, Ji RR, et al. (2006). Induction of CB1 cannabinoid receptor by inflammation in primary afferent neurons facilitates antihyperalgesic effect of peripheral CB1 agonist. Pain 124: 175-183.
5. Andrews PC, Krinsky NI, (1981). The reductive cleavage of myeloperoxidase in half, producing enzymatically active hemi-peroxidase. J Biol Chem 256: 4211-4218.
6. Aquila S, Guido C, Santoro A, Gazzerro P, Laezza C, Baffa MF, Andò S, Bifulco M,. (2010). Rimonabant (SR141716) induces metabolism and acquisition of fertilizing ability in human sperm. Br J Pharmacol 159: 831-841.
7. Banno T, Gazel A, Blumenberg M, (2005). Pathway-specific profiling identifies the NF-kappa B-dependent tumor necrosis factor alpha-regulated genes in epidermal keratinocytes. J Biol Chem 280: 18973-18980.
8. Bradford MM., (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
9. Bradley PP, Priebat DA, Christensen RD, Rothstein G, (1982). Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78: 206-209.
10. Carai MA, Colombo G, Gessa GL, (2005). Rimonabant: the first therapeutically relevant cannabinoid antagonist. Life Sci 77: 2339-2350.
11. Chen C, Edelstein LC, Gelinas C, (2000). The Rel/NF-kB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 20: 2687-2695.
12. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL, (1998). Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 63: PL113-PL117.
13. Costa B, (2007). Rimonabant: more than an anti-obesity drug? Br J Pharmacol 150: 535-537.
14. Costa B, Trovato AE, Colleoni M, Giagnoni G, Zarini E, Croci T, (2005). Effect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve. Pain 116: 52-61.
15. Croci T, Zarini E, (2007). Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvantinduced arthritis in obese and lean rats. Br J Pharmacol 150: 559-566.
16. Croci T, Landi M, Galzin AM, Marini P, (2003). Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. Br J Pharmacol 140: 115-122.
17. Di Marzo V, Matias I, (2005). Endocannabinoid control of food intake and energy balance. Nat Neurosci 8: 585-589.
18. Di Marzo V, Szallasi A., (2008). Rimonabant in rats with a metabolic syndrome: good news after the depression. Br J Pharmacol 154: 915-917.
19. Dobrosi N, Tóth BI, Nagy G, Dózsa A, Géczy T, Nagy L, et al. (2008). Endocannabinoids enhance lipid synthesis and apoptosis of human sebocytes via cannabinoid receptor-2-mediated signaling. FASEB J 22: 3685-3695.
20. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S, et al. (2005). Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54: 2838-2843.
21. Gazzerro P, Malfitano AM, Proto MC, Santoro A, Pisanti S, Caruso MG, et al. (2010). Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin Oncol Rep 23: 171-175.
22. Giangaspero A, Ponti C, Pollastro F, Del Favero G, Della Loggia R, Tubaro A, Appendino G, Sosa, S, (2009). Topical anti-inflammatory activity of eupatilin, a lipophilic flavonoid from mountain wormwood (Artemisia umbelliformis Lam.). J Agric Food Chem 57: 7726-7730.
23. Guindon J, Hohmann AG,. (2008). Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 153: 319-334.
24. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M, (1999). NF-κB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 19: 2690-2698.
25. Hohmann AG, (2002). Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem Phys Lipids 121: 173-190.
26. Hu X, Yee E, Harlan JM, Wong F, Karsan A, (1998). Lipopolysaccharide induces the antiapoptotic molecules, A1 and A20, in microvascular endothelial cells. Blood 92: 2759-2765.
27. Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, et al. (2005). CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A. 102: 3093-3098.
28. Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A, et al. (2005). The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 19: 1567-1569.
29. Jhaveri MD, Richardson D, Chapman V, (2007). Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br J Pharmacol 152: 624-632.
30. Karsak M, Gaffal E, Date R, Wang-Eckhardt L, Rehnelt J, Petrosino S, et al. (2007). Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 316: 1494-1497.
31. Kumar S, Bryant CS, Chamala S, Qazi A, Seward S, Pal J, et al. (2009). Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells. Mol Cancer 8: 26.
32. Maccarrone M, Di Rienzo M, Battista N, Gasperi V, Guerrieri P, Rossi A, et al. (2003). The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermal differentiation through CB1 receptordependent inhibition of protein kinase C, activation protein-1, and transglutaminase. J Biol Chem 278: 33896-33903.
33. Malfitano AM, Laezza C, Pisanti S, Gazzerro P, Bifulco M, (2008). Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells. Br J Pharmacol 153: 1003-1010.
34. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C, et al. (2006). Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91: 3171-3180.
35. Mbvudula EC, Rainsford KD, Bunning RAD, (2004). Cannabinoids in pain and inflammation. Inflammopharmacology 12: 99-114.
36. Miller AM, Stella N, (2008). CB2 receptor-mediated migration of immune cells: it can go either way. Br J Pharmacol 153: 299-308.
37. Paradisi A, Pasquariello N, Barcaroli D, Maccarrone M, (2008). Ananamide regulates keratinocyte differentiation by inducing DNA methylation in a CB1 receptor-dependent manner. J Biol Chem 283: 6005-6012.
38. Pertwee RG, (2009). Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 156: 397-411.
39. Petrosino S, Cristino L, Karsak M, Gaffal E, Ueda N, Tüting T, et al. (2010). Protective role of palmitoylethanolamide in contact allergic dermatitis. Allergy 65: 698-711
40. Portella G, Cumming SA, Liddell J, Cui W, Ireland H, Akhurst RJ, et al. (1998) Transforming growth factor beta is essential for spindle cell conversion of mouse skin carcinoma in vivo: implications for tumor invasion. Cell Growth Differ 9: 393-404.
41. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, et al. (2003). Anti-obesity effect of SR 141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 284: R345-R353.
42. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, et al. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350: 240-244.
43. Rinaldi-Carmona M, Barth F, Héaulme M, Alonso R, Shire D, Congy C, et al. (1995). Biochemical and pharmacological characterisation of SR 141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 56: 1941-1947.
44. Santoro A, Gazzerro P, Malfitano AM, Pisanti S, Laezza C, Bifulco M, (2008). Reply to the letter to the editor 'Long-term cannabinoid receptor (CB1) blockade in obesity: implications for the development of colorectal cancer'. Int J Cancer 123: 243-244.
45. Santoro A, Pisanti S, Grimaldi C, Izzo A, Borrelli F, Proto MC, et al. (2009). Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon. Int J Cancer 125: 996-1003.
46. Sarnataro D, Pisanti S, Santoro A, Gazzerro P, Malfitano AM, Laezza C, et al. (2006). The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid rafts mediated mechanism. Mol Pharmacol 70: 1298-1306.
47. Schmidt-Ullrich R, Tobin DJ, Lenhard D, Schneider P, Paus R, Scheidereit C, (2006). NF-kappaB transmits Eda A1/EdaR signalling to activate Shh and cyclin D1 expression, and controls post-initiation hair placode down growth. Development 133: 1045-1057.
48. Simiand J, Keane M, Keane PE, Soubrié P, (1998). SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 9: 179-181.
49. Smith SR, Terminelli C, Denhardt G, (2000). Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. J Pharmacol Exp Ther 293: 136-150.
50. Ständer S, Schmelz M, Metze D, Luger T, Rukwied R, (2005). Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci 38: 177-188.
51. Telek A, Bíró T, Bodó E, Tóth BI, Borbíró I, Kunos G, et al. (2007). Inhibition of human hair follicle growth by endo- and exocannabinoids. FASEB J 21: 3534-3541.
52. Tubaro A, Dri, P, Delbello G, Zilli C, Della Loggia R, (1985). The Croton oil ear test revisited. Agents Actions 17: 347-349.
53. Walker JM, Huang SM, (2002). Cannabinoid analgesia. Pharmacol Therapeut 95: 127-135.
54. Wilkinson JD, Williamson EM, (2007). Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. J Dermatol Sci 45: 87-92.
55. Zhang J, Warren MA, Shoemaker SF, Ip MM, (2007). NFkappaB1/p50 is not required for tumor necrosis factor-stimulated growth of primary mammary epithelial cells: implications for NFkappaB2/p52 and RelB. Endocrinology 148: 268-278.
56. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C, (1999). The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kB that blocks TNFa-induced apoptosis. Genes Dev 13: 382-387.